The Safety of available immunotherapy for the treatment of glioblastoma.

Published

Journal Article (Review)

INTRODUCTION: Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Current standard of care involves maximal surgical resection combined with adjuvant chemoradiation. Growing support exists for a role of immunotherapy in treating these tumors with the goal of targeted cytotoxicity. Here we review data on the safety for current immunotherapies being tested in GBM. Areas covered: Safety data from published clinical trials, including ongoing clinical trials were reviewed. Immunotherapeutic classes currently under investigation in GBM include various vaccination strategies, adoptive T cell immunotherapy, immune checkpoint blockade, monoclonal antibodies, and cytokine therapies. Trials include children, adolescents, and adults with either primary or recurrent GBM. Expert opinion: Based on the reviewed clinical trials, the current immunotherapies targeting GBM are safe and well-tolerated with minimal toxicities which should be noted. However, the gains in patient survival have been modest. A safe and well-tolerated combinatory immunotherapeutic approach may be essential for optimal efficacy towards GBM.

Full Text

Duke Authors

Cited Authors

  • Farber, SH; Elsamadicy, AA; Atik, AF; Suryadevara, CM; Chongsathidkiet, P; Fecci, PE; Sampson, JH

Published Date

  • March 2017

Published In

Volume / Issue

  • 16 / 3

Start / End Page

  • 277 - 287

PubMed ID

  • 27989218

Pubmed Central ID

  • 27989218

Electronic International Standard Serial Number (EISSN)

  • 1744-764X

Digital Object Identifier (DOI)

  • 10.1080/14740338.2017.1273898

Language

  • eng

Conference Location

  • England